Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers
04:10pm, Friday, 07'th Jun 2024
Geron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug Administration (FDA) approved the biopharma company's drug Rytelo for those with rare blood cancers.
Geron Corporation: FDA Approval Fuels Stock Price Surge
12:57pm, Friday, 07'th Jun 2024
The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation NASDAQ: GERN into the spotlight, sparking a surge in Geron's stock price and attracting heightened attention from inve
Why Is Geron (GERN) Stock Up 18% Today?
11:02am, Friday, 07'th Jun 2024
Geron (NASDAQ: GERN ) stock is heading higher on Friday after getting approval from the Food and Drug Administration (FDA) for RYTELO. RYTELO is the company's “adult patients with low- to intermedi
Geron shares surge after U.S. FDA approves blood disorder drug
06:04am, Friday, 07'th Jun 2024
Shares of Geron rose almost 16% on Friday before market, a day after getting its first approval from the U.S. Food and Drug Administration for a drug to treat transfusion-dependent anemia in patients
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
Geron Corporation: A High-Risk Deal With A Good Chance Of Success
05:49pm, Thursday, 23'rd May 2024
Geron Corporation's unique product, Imetelstat, could potentially bring real benefits to hematological diseases with a Total Addressable Market value of $7 billion by 2031. Clinical studies have shown
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 16'th May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an a
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
09:21am, Thursday, 02'nd May 2024
Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.07 per share a year ago.
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
07:00am, Thursday, 02'nd May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t
The Top 3 Penny Stocks to Buy in April 2024
06:46am, Thursday, 02'nd May 2024
Investing in certain penny stocks to buy during a volatile economy can present unique opportunities for investors. Typically priced below $5 per share (at a discount), these stocks often exhibit heigh
Geron: FDA PDUFA Review With Continued Imetelstat Advancement
04:23pm, Wednesday, 01'st May 2024
Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome. The FDA Oncologic Drugs Ad
3 'Buy-Rated' Biotech Stocks Under $10
04:39am, Sunday, 28'th Apr 2024
Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presente
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
04:30pm, Thursday, 25'th Apr 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results a
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 18'th Apr 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an a
Geron to Participate at Upcoming Investor Conferences in April
04:30pm, Wednesday, 03'rd Apr 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executi
